For the quarter ending 2025-09-30, SNDX has $551,792K in assets. $436,362K in debts. $116,808K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 116,808 | 108,636 | ||
| Short-term investments | 319,171 | 346,597 | ||
| Accounts receivable, net | 25,403 | 19,454 | ||
| Inventory | 25,000 | 17,696 | ||
| Short-term deposits | 18,195 | 13,473 | ||
| Other receivable, net | 0 | 3,629 | ||
| Collaboration receivable, net | 15,736 | 12,316 | ||
| Prepaid expenses and other current assets | 9,517 | 9,875 | ||
| Total current assets | 529,830 | 531,676 | ||
| Long-term investments | 20,146 | 62,627 | ||
| Property and equipment, net | 128 | 0 | ||
| Right-of-use asset, net | 1,471 | 1,629 | ||
| Restricted cash | 217 | 217 | ||
| Total assets | 551,792 | 596,149 | ||
| Accounts payable | 13,826 | 17,353 | ||
| Collaboration payable, net | 0 | 0 | ||
| Royalty payable | - | 4,783 | ||
| Accrued expenses and other current liabilities | 77,105 | 71,066 | ||
| Current portion of royalty interest financing liability | 22,925 | 19,435 | ||
| Current portion of right-of-use liability | 329 | 344 | ||
| Current portion of capital lease | 2 | 6 | ||
| Total current liabilities | 114,187 | 112,987 | ||
| Royalty interest financing liability, less current portion | 320,985 | 324,413 | ||
| Right-of-use liability, less current portion | 1,190 | 1,325 | ||
| Total long-term liabilities | 322,175 | 325,738 | ||
| Total liabilities | 436,362 | 438,725 | ||
| Common stock, 0.0001 par value, 200,000,000 shares authorized 86,905,343 and 85,694,443 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 9 | 9 | ||
| Additional paid-in capital | 1,553,462 | 1,534,981 | ||
| Accumulated other comprehensive gain | 525 | 285 | ||
| Accumulated deficit | -1,438,566 | -1,377,851 | ||
| Total stockholders equity | 115,430 | 157,424 | ||
| Total liabilities and stockholders equity | 551,792 | 596,149 | ||
Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (SNDX)